Physician profile
Dylan Eugene Greeney
NPI 1033639190
$8,131.36
in general payments reported to CMS, 2019-2025
27 companies · $2,197 in 2025
The $2,197 reported for 2025 was more than what 78% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $323 · 2020: $110 · 2021: $582 · 2022: $1,292 · 2023: $1,808 · 2024: $1,819 · 2025: $2,197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,476 · Education: $348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,475.65 |
| Education | $347.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,909.40 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $687.98 | 2022-2025 | |
| Janssen Biotech, INC. | $678.45 | 2022-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $585.79 | 2021-2025 | Absorica Ld, Winlevi, Ilumya |
| Lilly USA, LLC | $549.18 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $491.99 | 2022-2025 | Sotyktu |
| Amgen INC. | $467.50 | 2021-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $450.21 | 2021-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $397.81 | 2022-2025 | Nemluvio, Aklief |
| Genzyme Corporation | $275.76 | 2022-2025 | |
| Leo Pharma INC. | $219.44 | 2021-2025 | Adbry, Spevigo, Anzupgo |
| Incyte Corporation | $218.55 | 2021-2025 | Opzelura |
| Merz North America, INC. | $192.49 | 2024-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $169.45 | 2021-2025 | Jublia, Cabtreo |
| Pfizer INC. | $153.86 | 2023-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $152.94 | 2023-2025 | Zoryve |
| Vyne Pharmaceuticals INC. | $134.43 | 2021 | |
| Celgene Corporation | $104.92 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.03 | 2022-2025 | Spevigo |
| Krystal Biotech INC | $46.00 | 2025 | Vyjuvek |
| Ucb, INC. | $42.73 | 2024-2025 | Bimzelx |
| Genentech USA, INC. | $31.77 | 2021 | |
| Botanix Sb INC | $21.26 | 2025 | Sofdra |
| Biofrontera INC. | $17.54 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Organogenesis INC. | $15.28 | 2024 | |
| Dermavant Sciences, INC. | $15.07 | 2023 | Vtama |
| Organon LLC | $11.53 | 2025 | Hadlima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dylan Greeney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.